LUME-Ovar 1: Nintedanib (BIBF 1120) or Placebo in Combination With Paclitaxel and Carboplatin in First Line Treatment of Ovarian Cancer

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
Boehringer Ingelheim
ClinicalTrials.gov Identifier:
NCT01015118
First received: November 9, 2009
Last updated: February 5, 2014
Last verified: February 2014

November 9, 2009
February 5, 2014
November 2009
April 2013   (final data collection date for primary outcome measure)
progression free survival [ Time Frame: 41 months ] [ Designated as safety issue: No ]
progression free survival [ Time Frame: 41 months ]
Complete list of historical versions of study NCT01015118 on ClinicalTrials.gov Archive Site
  • progression free survival according to Response Evaluation Criteria In Solid Tumors 1.1 criteria [ Time Frame: 41 months ] [ Designated as safety issue: No ]
  • overall survival [ Time Frame: 41 months ] [ Designated as safety issue: No ]
  • time to tumour marker progression [ Time Frame: 41 months ] [ Designated as safety issue: No ]
  • objective response [ Time Frame: 41 months ] [ Designated as safety issue: No ]
  • incidence and intensity of adverse events [ Time Frame: 41 months ] [ Designated as safety issue: No ]
  • changes in safety laboratory parameters [ Time Frame: 41 months ] [ Designated as safety issue: No ]
  • progression free survival according to Response Evaluation Criteria In Solid Tumors 1.1 criteria [ Time Frame: 41 months, 78 months ]
  • overall survival [ Time Frame: 41 months, 78 months ]
  • time to tumour marker progression [ Time Frame: 41 months, 78 months ]
  • objective response [ Time Frame: 41 months, 78 months ]
  • incidence and intensity of adverse events [ Time Frame: 41 months, 78 months ]
  • changes in safety laboratory parameters [ Time Frame: 41 months, 78 months ]
Not Provided
Not Provided
 
LUME-Ovar 1: Nintedanib (BIBF 1120) or Placebo in Combination With Paclitaxel and Carboplatin in First Line Treatment of Ovarian Cancer
Multicenter, Randomised, Double-blind Phase III Trial to Investigate the Efficacy and Safety of BIBF 1120 in Combination With Carboplatin and Paclitaxel Compared to Placebo Plus Carboplatin and Paclitaxel in Patients With Advanced Ovarian Cancer

The trial will be performed to evaluate if BIBF 1120 in combination with paclitaxel and carboplatin is more effective than placebo in combination with paclitaxel and carboplatin in first-line treatment of patients with advanced ovarian cancer. Safety information about BIBF1120/paclitaxel/carboplatin will be obtained.

Not Provided
Interventional
Phase 3
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment
  • Ovarian Neoplasms
  • Peritoneal Neoplasms
  • Drug: Placebo
    comparator to BIBF 1120
  • Drug: BIBF 1120
    comparison of BIBF 1120 in combination with chemotherapy and placebo in combination with chemotherapy (paclitaxel/carboplatin)
  • Experimental: BIBF 1120
    patients to receive BIBF 1120 standard dose twice daily PO in combination with combination with carboplatin and paclitaxel
    Intervention: Drug: BIBF 1120
  • Placebo Comparator: Placebo
    patients to receive capsules identical to those containing BIBF 1120 in combination with combination with carboplatin and paclitaxel
    Intervention: Drug: Placebo
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
1375
July 2016
April 2013   (final data collection date for primary outcome measure)

Inclusion criteria:

  • first diagnosis of histologically confirmed epithelial ovarian cancer, fallopian tube or primary peritoneal cancer
  • International Federation of Gynecology and Obstetrics (FIGO) Stages IIB - IV
  • females, age 18 years or older
  • life expectancy of at least 6 months
  • Eastern Cooperative Oncology Group (ECOG) performance status 0, 1 or 2
  • prior surgery, defined as either (a) debulking surgery with maximum surgical effort at cytoreduction with the goal of no residual disease or (b) biopsy or limited surgery in patients with stage IV disease for whom surgical debulking was not considered appropriate, if diagnosis is confirmed by histology and no surgery is planned prior to disease progression (including interval debulking surgery)
  • patient has given written informed consent which must be consistent with the International Conference on Harmonization - Good Clinical Practice (ICH-GCP) and local legislation
  • planned application of first dose of chemotherapy after wound healing, but no later than 10 weeks after surgery

Exclusion criteria:

  • histologic diagnosis of a benign or borderline tumour or of a malignant tumour of non-epithelial origin of the ovary, the fallopian tube or the peritoneum
  • planned surgery within 124 weeks after randomisation in this trial, including interval debulking surgery
  • clinically relevant non-healing wound, ulcer or bone fracture
  • clinical symptoms or signs of gastrointestinal obstruction that require parenteral nutrition or hydration
  • brain metastases
  • pre-existing sensory or motor neuropathy Common Terminology Criteria for Adverse Events (CTCAE) grade 2 or higher, except due to trauma
  • history of major thromboembolic event
  • known inherited or acquired bleeding disorder
  • significant cardiovascular diseases
  • clinically relevant pericardial effusion
  • history of a cerebral vascular accident, transient ischemic attack or subarachnoid haemorrhage within the past 6 months
  • inadequate safety laboratory values
  • serious infections in particular if requiring systemic antibiotic (antimicrobial, antifungal) or antiviral therapy, including Hepatitis B, Hepatitis C, Human Immunodeficiency Virus (HIV)
  • poorly controlled diabetes mellitus or other contraindication to high dose corticosteroid therapy
  • gastrointestinal disorders or abnormalities that would interfere with absorption of the study drug
  • other malignancy diagnosed within the past 5 years. In exception to this rule, the following malignancies may be included if adequately treated: non-melanomatous skin cancer, cervical carcinoma in situ, carcinoma in situ of the breast, low risk endometrial cancer
  • prior systemic therapy for ovarian cancer (e.g. chemotherapy, monoclonal antibody therapy, oral targeted therapy, hormonal therapy)
  • prior systemic cytotoxic chemotherapy
  • prior treatment with BIBF 1120 or any other angiogenesis inhibitor
  • prior radiotherapy
  • serious illness or concomitant non-oncological disease such as neurologic, psychiatric or infectious disease or a laboratory abnormality that may increase the risk associated with study participation or study drug administration
  • Women of childbearing potential who are sexually active and not using a highly effective method of birth control during the trial and for at least twelve months after the end of active therapy.
  • pregnancy or breast feeding
  • psychological, familial, sociological or geographical factors potentially hampering compliance with the study protocol and follow-up schedule
  • active alcohol or drug abuse
  • patients unable to comply with the protocol
  • any contraindications for therapy with paclitaxel or carboplatin
  • treatment with other investigational drugs or participation in another clinical trial testing a drug within the past four weeks before start of therapy or concomitantly with this trial
Female
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States,   Australia,   Austria,   Belgium,   Canada,   Czech Republic,   Denmark,   Finland,   France,   Germany,   Greece,   Italy,   Netherlands,   Norway,   Poland,   Portugal,   Russian Federation,   Slovakia,   Spain,   Sweden,   Ukraine,   United Kingdom
 
NCT01015118
1199.15, AGO-OVAR12, 2008-006831-10
Not Provided
Boehringer Ingelheim
Boehringer Ingelheim
Not Provided
Study Chair: Boehringer Ingelheim Boehringer Ingelheim
Boehringer Ingelheim
February 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP